Regeneron, Abiomed Hit New Highs On Strong Guidance

By | August 4, 2015

Scalper1 News

Shares of top-rated medical firms Regeneron Pharmaceuticals and Abiomed hit new highs in the stock market early Tuesday after both companies beat quarterly earnings estimates and raised guidance. Regeneron (REGN) reported Q2 earnings of $2.89 a share excluding one-time items, up 17% from a year earlier and 12 cents above analysts’ consensus, according to Thomson Reuters. Revenue jumped 50% to $999 million, $11 million more than Scalper1 News

Scalper1 News